Select Publications

Journal articles

Yap JY; Moens L; Lin MW; Kane A; Kelleher A; Toong C; Wu KHC; Sewell WA; Phan TG; Hollway GE; Enthoven K; Gray PE; Casas-Martin J; Wouters C; De Somer L; Hershfield M; Bucciol G; Delafontaine S; Ma CS; Tangye SG; Meyts I, 2021, 'Intrinsic Defects in B Cell Development and Differentiation, T Cell Exhaustion and Altered Unconventional T Cell Generation Characterize Human Adenosine Deaminase Type 2 Deficiency', Journal of Clinical Immunology, vol. 41, pp. 1915 - 1935, http://dx.doi.org/10.1007/s10875-021-01141-0

Gu B; De Gregorio M; Pipicella JL; Vande Casteele N; Andrews JM; Begun J; Connell W; D'Souza B; Gholamrezaei A; Hart A; Liew D; Radford-Smith G; Rimola J; Sutherland T; Toong C; Woods R; Wu Y; Xuan W; Williams AJ; Ng W; Ding NS; Connor S, 2021, 'Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol', BMJ open, vol. 11, http://dx.doi.org/10.1136/bmjopen-2020-043921

West TA; Sam M; Toong C, 2021, 'Comparison of three commercially available ELISA assays for anti-infliximab antibodies', Pathology, vol. 53, pp. 508 - 514, http://dx.doi.org/10.1016/j.pathol.2020.08.020

Wu Y; Lin B; Thilakanathan C; Lehmann P; Xuan W; Mohsen W; Toong C; Williams AJ; Ng W; Connor S, 2021, 'Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost-savings', Internal Medicine Journal, vol. 51, pp. 739 - 745, http://dx.doi.org/10.1111/imj.14644

Sam MJ; Connor SJ; Ng WWS; Toong CML, 2020, 'Comparative Evaluation of 4 Commercially Available ELISA Kits for Measuring Adalimumab and Anti-adalimumab Antibodies', Therapeutic Drug Monitoring, vol. 42, pp. 821 - 828, http://dx.doi.org/10.1097/FTD.0000000000000795

Grey A; Sam M; Lehmann P; Tannous A; Papathomas E; Makris A; Natfaji A; Wong J; Toong C, 2020, 'Estimating urinary losses of rituximab in membranous nephropathy with nephrotic range proteinuria', Pathology, vol. 52, pp. S41 - S41, http://dx.doi.org/10.1016/j.pathol.2020.01.149

West T; Sam M; Toong C, 2019, 'Comparison of three commercially-available elisa assays for anti-infliximab antibodies', Pathology, vol. 51, pp. S132 - S133, http://dx.doi.org/10.1016/j.pathol.2018.12.383

Malik S; Toong C, 2019, 'Monoclonal antibody interference in serum electrophoresis', Pathology, vol. 51, pp. S67 - S67, http://dx.doi.org/10.1016/j.pathol.2018.12.156

van der Poorten DK; McLeod D; Ahlenstiel G; Read S; Kwok A; Santhakumar C; Bassan M; Culican S; Campbell D; Wong SWJ; Evans L; Jideh B; Kane A; Katelaris CH; Keat K; Ko Y; Lee JA; Limaye S; Lin MW; Murad A; Rafferty M; Suan D; Swaminathan S; Riminton SD; Toong C; Berglund LJ, 2018, 'Gastric Cancer Screening in Common Variable Immunodeficiency', Journal of Clinical Immunology, vol. 38, pp. 768 - 777, http://dx.doi.org/10.1007/s10875-018-0546-3

Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW, 2017, 'Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases', Alimentary Pharmacology and Therapeutics, vol. 46, pp. 1037 - 1053, http://dx.doi.org/10.1111/apt.14368

Toong CML; Lee MWM; Connor S; Ng W, 2017, 'Response to: Comparison of infliximab drug measurement across three commercially available ELISA kits: author reply', Pathology, vol. 49, pp. 334 - 335, http://dx.doi.org/10.1016/j.pathol.2017.01.005

Lee MWM; Connor S; Ng W; Toong CML, 2016, 'Comparison of infliximab drug measurement across three commercially available ELISA kits', Pathology, vol. 48, pp. 608 - 612, http://dx.doi.org/10.1016/j.pathol.2016.07.001

Malkan A; Cappelen-Smith C; Beran R; Griffith N; Toong C; Wang MX; Cordato D, 2015, 'Anti-synthetase syndrome associated with anti PL-12 and anti-Signal recognition particle antibodies and a necrotizing auto-immune myositis', Journal of Clinical Neuroscience, vol. 22, pp. 396 - 398, http://dx.doi.org/10.1016/j.jocn.2014.04.031

Malkan A; Cordato D; Griffith N; Cappelen-Smith C; Toong C; Beran R, 2014, '10. Anti-synthetase syndrome associated with necrotizing myositis – Utility of myositis specific autoantibodies in predicting prognosis and choice of treatment', Clinical Neurophysiology, vol. 125, pp. e4 - e4, http://dx.doi.org/10.1016/j.clinph.2013.10.032

Barker R; Lehmann P; O’Neill S; Toong C, 2012, 'Phar lap and the filly: validating the anti-DSDNA-NCX IgG ELISA', Pathology, vol. 44, pp. S69 - S69, http://dx.doi.org/10.1016/s0031-3025(16)32777-5

Toong C, 2012, 'Use of cardiac MR imaging to evaluate the presence of myocarditis in autoimmune myositis: three cases', Rheumatology International, vol. 32, pp. 779 - 782, http://dx.doi.org/10.1007/s00296-009-1324-6

Toong C; Adelstein S; Phan TG, 2011, 'Clearing the complexity: immune complexes and their treatment in lupus nephritis', International Journal of Nephrology and Renovascular Disease, vol. 4, pp. 17 - 28, http://dx.doi.org/10.2147/IJNRD.S10233

Toong C; Puranik R; Adelstein S, 2009, 'Use of Cardiac MR Imaging to Evaluate the Presence of Myocarditis in Autoimmune Myositis: 3 Cases', Heart, Lung and Circulation, vol. 18, pp. S59 - S59, http://dx.doi.org/10.1016/j.hlc.2009.05.130

Toong C; Quin J, 2007, 'Investigation of the patient with suspected allergy', Medicine Today, vol. 8, pp. 49 - 56


Back to profile page